Trial Radar
Sign in

Study record

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

NCT07684235

RecruitingPhase 3

Sponsor: Amgen

Conditions: Obesity, Overweight

Interventions: Maridebart cafraglutide, Placebo

Countries: United States, Australia, Japan, Puerto Rico

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

1 events · 1 snapshots

1 recorded events1 registry snapshotsTracked since Sep 3, 2026Official CT.gov history
  1. Sep 3, 2026
    New TrialNotable

    Amgen started Phase 3 Obesity trial

    Registry state after update: Recruiting · Phase 3 · 4 countries

← Back to dashboard